Saturday, March 29, 2025 4:51:17 PM
ex,
Thanks for reposting your conspiracy theory about of the P3 data 😶
The DCVax-L P3 data is credible, was independently peer-reviewed, and demonstrates a significant survival benefit in a cancer representing an unmet need. The trial design (including crossover) was transparently discussed—the design was approved and the crossover was required by the FDA..
In addition to the P3, there is a DCVax-L combo trial that is ongoing at UCLA today which is a RCT with a placebo group.
Looking at NWBO overall, we might also consider the PII trials (also RTCs) involving their other DC platform at Roswell. The combo research there was recently approved to expand based on the independent evaluation of the peer-reviewers overseeing the grant funding. ✅️
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175992369
Thanks for reposting your conspiracy theory about of the P3 data 😶
The DCVax-L P3 data is credible, was independently peer-reviewed, and demonstrates a significant survival benefit in a cancer representing an unmet need. The trial design (including crossover) was transparently discussed—the design was approved and the crossover was required by the FDA..
In addition to the P3, there is a DCVax-L combo trial that is ongoing at UCLA today which is a RCT with a placebo group.
Looking at NWBO overall, we might also consider the PII trials (also RTCs) involving their other DC platform at Roswell. The combo research there was recently approved to expand based on the independent evaluation of the peer-reviewers overseeing the grant funding. ✅️
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175992369
Bullish
Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
